Drugs Made In America Acquisition Corp. (DMAAR) Net Income towards Common Stockholders (2025 - 2026)
Drugs Made In America Acquisition's (DMAAR) quarterly Net Income towards Common Stockholders came in at $1.1 million in Q2 2026, down 28.29% on a YoY basis from $1.6 million in Q2 2025, and up 630.63% quarter-over-quarter from $154147.0 in Q4 2025.
Powered by 
Analysis
Drugs Made In America Acquisition Corp. (DMAAR) Net Income towards Common Stockholders (2025 - 2026) Analysis & Trends
Drugs Made In America Acquisition (DMAAR) has reported Net Income towards Common Stockholders for 2 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 28.29% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $4.3 million (changed N/A YoY), and the FY2025 full-year result was $4.0 million, up 1517.64% from the prior year.
- Net Income towards Common Stockholders grew to $1.1 million in Q2 2026 per DMAAR's latest filing, from $154147.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.6 million in Q2 2025 and bottomed at $154147.0 in Q4 2025.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Dec 31, 2025 | 154,147.00 |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | 768,082.00 |